Search

Liraglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (as Victoza) and for chronic weight management (as Saxenda). It is supported by large phase 3 randomized controlled trials, including the LEADER cardiovascular outcomes trial and the SCALE obesity program. It is a once-daily injectable prescription medication.